[1]
Schumann J,Henrich EC,Strobl H,Prondzinsky R,Weiche S,Thiele H,Werdan K,Frantz S,Unverzagt S, Inotropic agents and vasodilator strategies for the treatment of cardiogenic shock or low cardiac output syndrome. The Cochrane database of systematic reviews. 2018 Jan 29;
[PubMed PMID: 29376560]
Level 1 (high-level) evidence
[2]
Kurmani S,Squire I, Acute Heart Failure: Definition, Classification and Epidemiology. Current heart failure reports. 2017 Oct;
[PubMed PMID: 28785969]
[3]
DiBianco R, Acute positive inotropic intervention: the phosphodiesterase inhibitors. American heart journal. 1991 Jun;
[PubMed PMID: 2035420]
[4]
Heidenreich PA, Bozkurt B, Aguilar D, Allen LA, Byun JJ, Colvin MM, Deswal A, Drazner MH, Dunlay SM, Evers LR, Fang JC, Fedson SE, Fonarow GC, Hayek SS, Hernandez AF, Khazanie P, Kittleson MM, Lee CS, Link MS, Milano CA, Nnacheta LC, Sandhu AT, Stevenson LW, Vardeny O, Vest AR, Yancy CW. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3:145(18):e895-e1032. doi: 10.1161/CIR.0000000000001063. Epub 2022 Apr 1
[PubMed PMID: 35363499]
Level 1 (high-level) evidence
[5]
McDonagh TA,Metra M,Adamo M,Gardner RS,Baumbach A,Böhm M,Burri H,Butler J,Čelutkienė J,Chioncel O,Cleland JGF,Coats AJS,Crespo-Leiro MG,Farmakis D,Gilard M,Heymans S,Hoes AW,Jaarsma T,Jankowska EA,Lainscak M,Lam CSP,Lyon AR,McMurray JJV,Mebazaa A,Mindham R,Muneretto C,Francesco Piepoli M,Price S,Rosano GMC,Ruschitzka F,Kathrine Skibelund A,ESC Scientific Document Group., 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European heart journal. 2021 Sep 21
[PubMed PMID: 34447992]
[6]
Asif M, Phosphodiesterase-III Inhibitors Amrinone and Milrinone on Epilepsy and Cardiovascular Activities. North American journal of medical sciences. 2012 Oct;
[PubMed PMID: 23112975]
[7]
Jentzer JC, Coons JC, Link CB, Schmidhofer M. Pharmacotherapy update on the use of vasopressors and inotropes in the intensive care unit. Journal of cardiovascular pharmacology and therapeutics. 2015 May:20(3):249-60. doi: 10.1177/1074248414559838. Epub 2014 Nov 28
[PubMed PMID: 25432872]
[8]
Cruickshank JM, Phosphodiesterase III inhibitors: long-term risks and short-term benefits. Cardiovascular drugs and therapy. 1993 Aug;
[PubMed PMID: 8241008]
[9]
Endoh M, Amrinone, forerunner of novel cardiotonic agents, caused paradigm shift of heart failure pharmacotherapy. Circulation research. 2013 Aug 2;
[PubMed PMID: 23908328]
[10]
Fearnley CJ,Roderick HL,Bootman MD, Calcium signaling in cardiac myocytes. Cold Spring Harbor perspectives in biology. 2011 Nov 1;
[PubMed PMID: 21875987]
Level 3 (low-level) evidence
[12]
Hellsten Y,Nyberg M,Jensen LG,Mortensen SP, Vasodilator interactions in skeletal muscle blood flow regulation. The Journal of physiology. 2012 Dec 15;
[PubMed PMID: 22988140]
[13]
Hermiller JB,Leithe ME,Magorien RD,Unverferth DV,Leier CV, Amrinone in severe congestive heart failure: another look at an intriguing new cardioactive drug. The Journal of pharmacology and experimental therapeutics. 1984 Feb;
[PubMed PMID: 6694112]
[14]
Wang Y,Yuan J,Qian Z,Zhang X,Chen Y,Hou X,Zou J, β2 adrenergic receptor activation governs cardiac repolarization and arrhythmogenesis in a guinea pig model of heart failure. Scientific reports. 2015 Jan 8;
[PubMed PMID: 25567365]
Level 2 (mid-level) evidence
[15]
Levy JH,Bailey JM, Amrinone: pharmacokinetics and pharmacodynamics. Journal of cardiothoracic anesthesia. 1989 Dec;
[PubMed PMID: 2521045]
[16]
Treadway G, Clinical safety of intravenous amrinone--a review. The American journal of cardiology. 1985 Jul 22
[PubMed PMID: 3895878]
[18]
Rich MW,Woods WL,Davila-Roman VG,Morello PJ,Kurz H,Barbarash R,Spinner L,Sperry J,Beckham V,Coulter L, A randomized comparison of intravenous amrinone versus dobutamine in older patients with decompensated congestive heart failure. Journal of the American Geriatrics Society. 1995 Mar
[PubMed PMID: 7884117]
Level 1 (high-level) evidence
[19]
Ward A,Brogden RN,Heel RC,Speight TM,Avery GS, Amrinone. A preliminary review of its pharmacological properties and therapeutic use. Drugs. 1983 Dec;
[PubMed PMID: 6360634]
[20]
Bottorff MB,Rutledge DR,Pieper JA, Evaluation of intravenous amrinone: the first of a new class of positive inotropic agents with vasodilator properties. Pharmacotherapy. 1985 Sep-Oct;
[PubMed PMID: 3906583]
[21]
Silverman BD,Merrill AJ Jr,Gerber L, Clinical effects and side effects of amrinone. A study of 24 patients with chronic congestive heart failure. Archives of internal medicine. 1985 May;
[PubMed PMID: 3994460]
[24]
Ansell J,Tiarks C,McCue J,Parrilla N,Benotti JR, Amrinone-induced thrombocytopenia. Archives of internal medicine. 1984 May;
[PubMed PMID: 6712412]
[25]
Ali D,Banerjee P, Inpatient Monitoring of Decompensated Heart Failure: What Is Needed? Current heart failure reports. 2017 Oct
[PubMed PMID: 28803272]
[26]
Lee H,Ryu K,Sohn Y,Kim J,Suh GY,Kim E, Impact on Patient Outcomes of Pharmacist Participation in Multidisciplinary Critical Care Teams: A Systematic Review and Meta-Analysis. Critical care medicine. 2019 Sep;
[PubMed PMID: 31135496]
Level 1 (high-level) evidence
[27]
Wever-Pinzon O,Drakos SG,Fang JC, Team-based Care for Advanced Heart Failure. Heart failure clinics. 2015 Jul
[PubMed PMID: 26142642]
[28]
Davidson PM,Newton PJ,Tankumpuan T,Paull G,Dennison-Himmelfarb C, Multidisciplinary management of chronic heart failure: principles and future trends. Clinical therapeutics. 2015 Oct 1
[PubMed PMID: 26412800]